Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Latest Articles
Submit an article Journal homepage
102
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Upadacitinib in Crohn’s disease: needs more insight

Avinash TiwariDepartment of Gastroenterology, Regency Hospital Ltd, Kanpur, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7365-1088View further author information
ORCID Icon
Received 16 May 2024, Accepted 03 Jun 2024, Published online: 17 Jun 2024

References

  • Dignass A, Esters P, Flauaus C. Upadacitinib in Crohn’s disease. Expert Opin Pharmacother. 2024;25(4):359–370. doi: 10.1080/14656566.2024.2333964
  • Loftus EV, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2023;388(21):1966–1980. doi: 10.1056/NEJMoa2212728
  • Peyrin-Biroulet L, Panaccione R, Louis E, et al. Upadacitinib achieves clinical and endoscopic outcomes in Crohn’s disease regardless of prior biologic exposure. Clin Gastroenterol Hepatol. 2024;S1542-3565(24):00253–2. doi: 10.1016/j.cgh.2024.02.026
  • 5-aminosalicylates | Abdominal Key [Internet]. [cited 2024 May 13]. Available from: https://abdominalkey.com/5-aminosalicylates/
  • Elford AT, Bishara M, Plevris N, et al. Real-world effectiveness of upadacitinib in Crohn’s disease: a UK multicentre retrospective cohort study. Frontline Gastroenterol [Internet]. 2024 [cited 2024 May 12];15(4):297–304. Available from: https://fg.bmj.com/content/early/2024/04/03/flgastro-2024-102668
  • Abreu MT, Phimister EG. JAK1 inhibition to treat Crohn’s disease. N Engl J Med. 2023;388(21):2005–2009. doi: 10.1056/NEJMe2301147
  • Jacobsen GE, Fernández I, Quintero MA, et al. Lamina propria phagocyte profiling reveals targetable signaling pathways in refractory inflammatory bowel disease. Gastro Hep Adv. 2022;1(3):380–392. doi: 10.1016/j.gastha.2022.01.005
  • Cao S, Colonna M, Deepak P. Pathogenesis of perianal fistulising crohn’s disease: current knowledge, gaps in understanding, and future research directions. J Crohns Colitis. 2023;17(6):1010–1022. doi: 10.1093/ecco-jcc/jjad008
  • Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi: 10.1053/j.gastro.2020.12.031
  • Dignass A, Rath S, Kleindienst T, et al. Review article: translating STRIDE-II into clinical reality – opportunities and challenges. Aliment Pharmacol Ther. 2023;58(5):492–502. doi: 10.1111/apt.17622

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.